DelveInsight's 'Myotonic Dystrophy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline myotonic ...

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Thursday, Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) saw its price target raised to $52.00 from the previous $42.00, while its stock rating remained at Outperform. The ...

Harmony Biosciences has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of -0.43, meaning that its share price is ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has already been able to receive FDA approval for its drug known as WAKIX [PITOLISANT]. It is for excessive daytime sleepiness [EDS] or cataplexy ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings ...

根据最近的SEC文件显示，Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)的董事Antonio Gracias已出售了公司大量股票。这些交易发生在11月1日和11月5日，涉及以每股30.3025美元的价格出售460万股，总计约1.394亿美元。在这些出售之后，Gracias及相关实体现持有Harmony Biosciences ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou to the Company's Board of Directors. Peter is Chief Executive Officer of a ...

Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $186.00 million for the quarter, compared to analysts’ expectations of $184.07 million.

Shareholders might have noticed that Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) filed its quarterly result this time last week. The early response was not positive, with shares down 6.9% to ...